Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

universities

Heart failure therapy embarks on a new era

After years of older, generic drugs, now new treatments are showing promising results

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

- PMLiVE

UK moves to accelerate digital health uptake

Aims to make London the global capital of digital health technologies

- PMLiVE

Mismanagement of Cancer Drugs Fund “unacceptable”

Influential committee of MPs finds the government still unable to assess CDF's patient benefit

Harnessing complexity

Companion diagnostics in oncology

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

- PMLiVE

Celgene uses ‘video views’ map in arthritis awareness drive

Be Counted! campaign highlights US views of its short films

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

French government begins investigation into fatal Biotrial study

First-in-man trial leaves one dead, five hospitalised

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

Roche Basel Switzerland

AbbVie and Roche hoping for speedy venetoclax approval

Leukaemia treatment could reach US and EU markets within months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links